Carin 330mg+200mg 20 Effervescent Tablets

NAME
CARIN ^ (R) - Effervescent tablets

PHARMACOTHERAPEUTIC CATEGORY
Analgesics and antipyretics.

ACTIVE PRINCIPLES
Ascorbic acid 200 mg and acetylsalicylic acid 330 mg.

EXCIPIENTS
Sodium bicarbonate, citric acid, glycocol, sodium benzoate.

INDICATIONS
Symptomatic therapy of flu, colds, headaches, migraines, muscle and rheumatic pains, neuralgia, periodic pains.

CONTRAINDICATIONS / SECONDARY EFFECT
Gastro-duodenal ulcer disease. Hypersensitivity to acetylsalicylic acid and salicylates. Hemorrhagic diathesis. Children and teenagers' diet under the age of 16. Doses greater than 100 mg / day during the third trimester of pregnancy. Severe heart failure.

DOSAGE
Adults and children over 16 years of age: 1 or 2 tablets every three hours, as needed. Do not exceed 8 tablets in 24 hours. In the treatment of elderly patients the posology must be carefully established by evaluating a possible reduction of the dosages indicated above.

STORAGE
Close the tube carefully after use. Store at a temperature not exceeding 25 degrees C.

WARNINGS
The intake of the preparations for oral use must take place with a full stomach. Use with caution in cases of asthma and gout. Caution is required (discuss with your doctor or pharmacist) before starting treatment in patients with a history of hypertension and / or heart failure as fluid retention, hypertension and edema have been reported in association with NSAID treatment. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. Cardiovascular and cerebrovascular effects: Clinical studies and epidemiological data suggest that the use of some NSAIDs (especially at high doses and for long-term treatments) may be associated with a modest increased risk of arterial thrombotic events (e.g. myocardial infarction or stroke). There are currently insufficient data to exclude a similar risk for acetylsalicylic acid when it is administered at the daily dose of 330-2640 mg. This medicinal product should not be used in children and young people under the age of 16.

INTERACTIONS
It can interact with anticoagulants, uricosurics, sulfonylureas and hypoglycemic agents.

SIDE EFFECTS
Otovestibular disorders (buzzing, etc.), gastrointestinal disorders (pains, etc.), haemorrhagic phenomena (epistaxis, gingivores), hypersensitivity phenomena (skin rashes, etc.). Fluid retention, hypertension and edema have been reported in association with NSAID treatment. Clinical studies and epidemiological data suggest that the use of some NSAIDs (especially at high doses and for long-term treatment) may be associated with a modest increased risk of arterial thrombotic events (e.g. myocardial infarction or stroke).

PREGNANCY AND BREASTFEEDING
The use in pregnancy for long periods and the administration in the last three months of pregnancy must take place only on medical prescription since acetylsalicylic acid can cause haemorrhagic phenomena in the fetus and mother, delivery delays and, in the unborn child, early closure of the learned of Botallo. Clinical studies indicate that doses up to 100 mg / day can be considered safe for use only in obstetrics, which requires specialized monitoring. There are insufficient clinical findings related to the use of doses above 100 mg / day up to 500 mg / day. Therefore the recommendations below for doses of 500 mg / day and above also apply to this dosage range. Inhibition of prostaglandin synthesis can negatively affect pregnancy and / or embryo / fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of heart malformations was increased from less than 1% to approximately 1.5%. The risks have been estimated to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to cause an increase in pre- and post-implantation loss and embryo / fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular, has been reported in animals administered with prostaglandin inhibitors during the organogenetic period. If acetylsalicylic acid is used by a woman attempting to conceive or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible.During the third trimester of pregnancy all inhibitors of prostaglandin synthesis can expose: the fetus to cardiopulmonary toxicity (with premature closure of the arterial duct and pulmonary hypertension) and renal dysfunction (which can progress to renal insufficiency with oligo-hydroamnios); and the mother and the newborn, at the end of pregnancy, to possible prolongation of the bleeding time and antiplatelet effect (which can also occur at very low doses) and inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, acetylsalicylic acid in doses higher than 100 mg / day is contraindicated during the last trimester of pregnancy.